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A suitable matrix system of ketorolac tromethamine (KTR) 
formulation has been developed with the aim of increasing the 
contact time, achieving controlled release, reducing the 
frequency of administration, improving patient compliance. In 
this concern an enteric-coated KTR matrix tablet intended for 
specific delivery of drugs to the colon by combining the use of a 
time dependent core with a pH-sensitive film coating. Eudragit 
L100, with a threshold pH 7, was selected as coating material.  
New formulation is proved to be noble as to KTR delivery through 
both gastrointestinal and colonic system. New formulation is 
considered to reduce gastrointestinal side effects and achieve 
high local drug concentration at the afflicted site in the gastro-
intestine and colon. 
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INTRODUCTION 
The magnitude of these fluctuations due 
to the administration of drugs in conventional 
dosage forms depends on the rates of 
absorption, distribution and elimination and 
dosing intervals. Again though intravenous 
administration of drug provides the advantages 
like direct entry of drug into the systemic 
circulation, and control of circulating drug 
levels but this drug delivery has certain 
disadvantages, which would require 
hospitalization of the patients and close medical 
supervision of the medication (Joseph et 
al.1987). The novel drug delivery system 
includes transdermal drug delivery system, 
mucoadhesive drug delivery system, nasal drug 
delivery system, gastrointestinal, colonic drug 
delivery system etc. 
Ketorolac tromethamine (KTR) (Figure 
1), a potent nonnarcotic analgesic with 
moderate anti-inflammatory activity, has been 
investigated extensively for use in post-
operative analgesia and has an excellent 
applicability in the emergency treatment of 
postoperative cancer pain and in the treatment 
of migraine pain (Andrade et al., 1994). As the 
biological half-life of KTR is 4–6 h frequent 
dosing is necessary to sustain the action of drug 
to alleviate pain in postoperative patients. It 
causes gastro intestinal complications including 
irritation, ulcer, bleeding and perforation when 
administered as the conventional formulation 
(Shankar and Mishra, 2003; Shyamala and 
Sanmathi, 2001). Although  oral bioavailability 
of KTR was reported to be 90% with a very 
low first pass metabolism, its short biological 
half-life and many adverse effects, such as 
upper abdominal pain and gastrointestinal 




Figure  1.  Structural  formulae  for  ketorolac 
tromethamine
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Oral administration of different dosage 
forms has high patient acceptance due to 
greater flexibility in design of dosage form but 
the gastrointestinal tract presents several 
formidable barriers to drug delivery (Girish et 
al., 2006). Colon has a large amount of 
lymphoma tissue negligible brush boarder 
membrane activity and much less pancreatic 
enzymatic activity as compared with the small 
intestine. Therefore, in oral colon-specific drug 
delivery system facilitates direct absorption in 
to the blood (Chourasia, Jain, 2003) and this 
delivery by oral route has gained increased 
importance from last two decades to treat local 
diseases associated with colon (Vincent, 2002). 
The traditional approaches for colon targeting 
are prodrug formulation, pH-sensitive drug 
delivery, time-dependent systems and microbial 
degradation methods to formulate different 
dosage forms (Vemula, 2009). With 
conventional tabletting facilities and less 
processing variables, formulation of matrix 
tablets is inexpensive method and easy to 
manufacture (Demiroz et al., 2004).  
 
 
R=H or CH2 CH3 
 
Figure 2. Ethyl cellulose, a synthetic retardant 
widely used as a release agent 
 
Preparation of matrix tablets is simple 
method compared to other methods like tablets 
coated with different polymers and chemical 
conjugation of drug. Ethyl cellulose (Figure 2), 
a synthetic retardant, is widely used as an 
extended release agent in the pharmaceutical 
industry. Ethyl cellulose is an inert, 
hydrophobic polymer and is essentially 
tasteless, odorless, colorless, non-caloric, and 
physiologically inert. As solvent-based tablet 
and pellet coating, tablet binder, to prepare 
microcapsules and microspheres Ethyl cellulose 
has long been used. It is also used both as film- 
and matrix- forming material for sustained-
release dosage forms. It shows good swelling 
and gel-forming properties and its controlled 
release mechanism is applied to formulate 
colon specific matrix tablets. Ethyl cellulose can 
be applied to prepare sustained release tablets 
by direct compression. Lower viscous grades of 
ethyl cellulose or a higher percentage of ethyl 
cellulose in the formulation can slow down the 
drug release rate. Furthermore, it has been seen 
that lower viscous grades produce harder 
tablets and a smaller particle size leads to a 
slower release rate. Membranes made of only 
Ethyl cellulose are water insoluble with good 
mechanical properties, but poor water 
permeability. These properties strongly 
decrease the release of an active substance. 
Sodium alginate, a hydrophilic biopolymer is 
used to increase the permeability of films. 
Combination of both swells and drug 
molecules begin to move out of the system by 
diffusion.  
In fact the polymers used to achieve 
colon targeting should be able to withstand, 
unchanged, the lower pH values of stomach 
and small intestine and dissolve at the neutral 
or slightly alkaline pH of the terminal ileum 
(Chourasia, 2003). Keterolac tromethamine 
(KTR), a non-steroidal anti-inflammatory drug 
was efficient to treat inflammation and pain 
related to colon. The frequent intake of 
NSAIDS like KTR leads to gastric ulceration, 
bleeding and other gastric complications 
(Chopra et al., 2008). Hence the objective is to 
develop new KTR formulation for the delivery 
through both gastrointestinal and colonic 
system. That is to reduce gastrointestinal side 
effects and achieve high local drug 
concentration at the afflicted site in the gastro-
intestine and colon, optimal therapeutic 
effectiveness and good patient compliance. 
 
MATERIAL AND METHODS 
KTR was gift sample from 
Glaxosmithkline Labs, Chittagong, Bangladesh. 
Na alginate, Mg stearate, Xanthine gum, Guar 
gum etc. of analytical grade (purity > 95%) 
were supplied by local agents of Aldrich Co. 
Ethyl cellulose (EC), actual viscosity 9.9 
centipoises, was obtained from ICN 
Biomedicals, Inc. (Ohio, USA). Eudragit L 100 
(purity > 95%) was gift samples from Opsonin 
Pharmaceutical Ltd. Bangladesh. All other 
chemicals and solvents used were also of 
pharmaceutical grade.  
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Powder characterization 
Before preparation of tablets, the 
powder mixtures of different formulations were 
evaluated for angle of repose, bulk density 
tapped density and compressibility index. The 
angle of repose (θ) was measured using fixed 






 …………………………………….... (1) 
 
Where, h is height of the cone and r is radius of 
the cone base. Angle of repose less than 30 
shows the free flowing of the material.  
The compressibility index or Carr‟s 
Index is a measure of the propensity of a 
powder to be compressed. Carr‟s Index is 
determined from the bulk and tapped densities.  
It is calculated using the following formula:  
 
Carr‟s Index =[ 
           
    
  ×100] …….…(2)  
 
Where, ρb is bulk density and ρtap is tapped 
density. 
 
Preparation of matrix tablets 
Wet granulation method was used to 
prepare the KTR matrix tablets. In this 
method,  accurately weighed quantities of KTR,  
ethyl cellulose and excipients other than glidant 
and lubricant were passed through 60-mesh 
sieve and mixed in a poly bag for 5-10min, then 
granules were prepared with the addition of 
sufficient amount of 5% poly vinyl pyrrolidine 
in alcohol as binding agent, dried and sieved to 
obtain uniform size granules. The obtained 
granules were lubricated with talc and 
magnesium stearate for another 5 min blending 
and the resultant mixture was compressed into 
tablets with 8 mm round flat punches using 16-
station rotary tabletting machine. The final 
weight of the tablet was adjusted to 200mg. 
Batch size was limited to 100g. The 
compositions of the matrix tablets (Table I).  
 
Composition and preparation of coating 
solution 
The compositions of coating solution are 
given in following table. Eudragit L100 was 
dissolved in organic solvent 5 % w/v (ethanol), 
and then it was stirred until the uniform 
mixture was formed. To this Talc 2% was 
added again it was stirred until uniform 
dispersion were formed. Then 1% plasticizer 
was added and it was stirred until uniform 
mixture was formed. Coating is done by using a 
conventional coating pan. The coating 
parameters (Table II).  
 
Table I. The compositions of the matrix tablets of proposed formulation 
 
Ingredient F1 F2 F3 F4 F5 F6 
Ketorolac tormethamine 10mg 10mg 10mg 10mg 10mg 10mg 
Xanthine gum 10mg 0 0 0 10mg 5mg 
Guar gum 0 10mg 0 0 10mg 5mg 
Ethyl cellulose 0 0 10mg 0 10mg 5mg 
Na alginate 0 0 0 10mg 10mg 5mg 
DCP 178mg 178 mg 178mg 178mg 148mg 168mg 
Mg stearate 2mg 2mg 2mg 2mg 2mg 2mg 
Total weight 200mg 200mg 200mg 200mg 200mg 200mg 
 
Table II. Composition of coating solution 
 
Sr. No Name of reagent Amount used 
1 Eudragit L 100 5% 
2 Talc 2% 
3 PEG 400 1% 
4 Ethanol QS 
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Preparation of enteric coated tablets 
The enteric coated tablets were prepared 
by using conventional coating pan. Coating 
solution was prepared by dissolving coating 
polymer in to the ethanol and uniform 
dispersion of coating solution was spray on the 
tablet bed under the following condition; spray 
air pressure kg/cm2, inlet temperature                
outlet temperature rotating speed of pan 
15rpm.  The coated tablets were dried for             
10-15mm. in coating pan by inching. The 
amount of coating was done up to 8 to 10% 
per tablets. The tablets were coated at different 
levels from about 10 to 20% w/w of solid 
eudragit. 
 
Evaluation of physical parameters 
Physical properties like weight variation, 
hardness and friability were studied for the 
prepared tablets. 20 tablets of each formulation 
were weighed using an electronic weighing 
balance (AW 120, Shimadzu Corporation, 
Japan) for estimating weight variation. 
Monsanto tablet hardness tester was used for 
measuring the hardness of six tablets. Using 
Roche friabilator, friability was determined on 
ten tablets. 
 
Determination of drug content 
Drug content was determined by 
crushing ten tablets and 100mg of the powder 
was accurately weighed and transferred into a 
100mL volumetric flask. Initially about 50mL 
of mobile phase was added to the volumetric 
flask and allowed to stand for 6-8h with 
intermittent shaking to ensure complete 
solubility of the drug. Then the volume was 
made up to 100mL with mobile phase, filtered 
and analyzed for KTR content by the HPLC 
method (Uddin et al. 2014). The mobile phase 
mixture of CH3OH, CH3CN and 0.02M 
NaH2PO4 by the composition of 50:10:40 (v/v) 
was optimized at isocratic program. A flow-rate 
of 0.20mL min-1 was chosen as a compromise 
analysis time. Reversed-phase Kinetex C18 (100 
× 2.10mm, 2.6μm) column and 320nm was 
selected for monitoring the drug using UV 
detector. Prior to the injection of the drug 
solution, the column was equilibrated for at 
least 30min with the mobile phase flowing 
through the system.  
 
In-vitro dissolution study 
In vitro drug release studies of KTR 
matrix tablets were carried out using USP 
XXIV Type I dissolution apparatus (Electro 
lab, TDT-08L) at a rotation speed of 50rpm 
and temperature of 37±0.5°C. In order to 
simulate the gastrointestinal transit conditions, 
the tablets were subjected to different 
dissolution media. Initially, the drug release was 
carried out for 2h in 0.1N HCl, 2h in buffer pH 
5.5 and finally in phosphate buffer pH 7.5 up 
to 24h. At specific time intervals, 5mL of the 
sample were withdrawn and replaced by an 
equal volume of fresh pre-warmed dissolution 
medium. The samples were filtered through 
0.45µm membrane filter (Millipore, USA) and 
analyzed at 322nm. 
 
In-vitro release kinetics 
To explain the pattern and the release 
mechanism from the formulations, the data 
obtained from the in vitro dissolution studies 
was fitted to zero order, first order and Higuchi 
models (Wu et al., 2007). The mechanism of 
drug release from these formulations was 
determined using Koresmeyer–Peppas model 
(Valluru et al., 2008). The mathematical 





    ……………………………(3) 
 
In which, Mt / Mα is the fractional amount of 
drug released at time t, k is a kinetic rate 
constant, and n is the diffusional exponent that 
characterizes the mechanism of drug release. 
The values of the coefficient were calculated 
using linear regression analysis between log Mt 
/ Mα and log t data obtained from drug release 
studies. The value of n was obtained as slope of 
the regression equation, and K was calculated 
as antilog of the intercept value (Asghar et al., 
2009). 
The n value is <0.45 suggests the Fickian 
release (diffusion controlled), for n is >0.45 and 
<0.89 it is non-Fickian release (diffusion              
and polymer relaxation), 0.89 for case II  
release (only relaxation and swelling), and for 
>0.89 it suggests super case II release 
(relaxation  and  erosion) for swellable systems.  
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replicates were kept in the humidity chamber 
maintained at 25°C and 75% RH for six 
months. Samples were collected after three and 
six months of storage and analyzed for the drug 
content and in vitro dissolution rate (Mathews, 
1999). 
 
RESULTS AND DISCUSSION 
Powder characterization 
The powder mixtures of different 
formulations were evaluated for angle of 
repose, bulk density, tapped density, 
compressibility index and their values (Table 
III). The average apparent and tapped bulk 
density values of 0.60±0.02 and 0.70±0.06, 
respectively. The average value of angle of 
repose and % Carr‟s index are 29.07±1.45 and 
10.27±0.76, respectively. 
 
Evaluation of physical parameters 
The physical properties of formulation 
matrix tablets (Table IV). In weight variation 
test, the pharmacopoeial limit for the tablets of 
not more than 7.5% of the average weight and 
found to be 203.11±1.2mg.  
Table III. Pre-formulation study (average) for proposed formulation 
Sr.no. Formulation Bulk density Tap density Compressibility Angle of repose (Ө) 
1 F1 0.58±0.04 0.67±0.05 9.63±0.8 26.89±0.4 
2 F2 0.62±0.4 0.72±0.04 11.35±0.3 28.25±0.7 
3 F3 0.61±0.04 0.71±0.04 10.2±0.4 29.74±0.4 
4 F4 0.65±0.04 0.75±0.03 9.29±0.1 28.77±0.3 
5 F5 0.59±0.04 0.61±0.04 10.88±0.4 29.62±0.7 
6 F6 0.59±0.05 0.79±0.04 10.29±0.09 31.15±0.06 
 average± SD 0.60±0.02 0.70±0.06 10.27±0.76 29.07±1.45 
 
*All values represent mean ± standard deviation, n=10 
 
Table IV The physical properties of new formulation 
 











1 F1 203.7±3.12 2.15±0.04 5.78±0.1 7.06±0.05 0.065±0.0 
2 F2 204.61±3.7 2.007±0.01 5.36±0.3 7.06±0.11 0.211±0.0 
3 F3 204.16±2.27 2.022±0.01 5.82±0.11 7.12±0.40 0.24±0.01 
4 F4 202.59±2.5 2.033±0.01 5.4±0.02 7.8±0.01 0.03±0.0 
5 F5 201.64±1.1 2.11±0.2 5.41±0.08 7.14±0.04 0.09±0.0 
6 F6 201.98±2.21 2.05±0.02 5.4±0.05 7.82±0.01 0.04±0.04 
 average± SD 203.11±1.2 2.06±0.05 5.52±0.21 7.33±0.37 0.12±0.9 
 
* All values represent mean ± standard deviation, n=10
For cylindrical systems like tablets, the n values
of  0.45  and  0.89  represent  pure  diffusion  or 
erosion controlled  release,  respectively
(Mundargi et al. 2007).
Drug-polymer interaction studies
  The  possible  interaction  between  KTR 
and  ethyl  cellulose  was  studied.  The  infrared 
spectra  of  KTR  and  optimized  formulation
(F4-F6)  recorded  within  400  to  4000cm-1 on 
FTIR  to  detect  the  drug-excipient  interactions. 
The  IR  spectra  for  the  test  samples  were 
obtained using KBr disk method using an FTIR 
spectrometer  (Model-883, Perkin  Elmer  FTIR, 
Perkin Elmer Inst. USA). The resultant spectra 
were compared for any possible changes in the 
peaks of the spectra. It is further confirmed by 
the peak purity of LC chromatogram.
Stability studies
  To  assess  the  drug  and  formulation 
stability,  stability  studies  were  done  according
to  ICH  and  WHO  guidelines.  Optimized 
formulation F4  sealed  in  aluminum  packaging 
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The hardness of the tablets was found to be in 
the range of 5.52±0.21kg/cm2. Another 
measure of tablets strength is friability. 
Conventional compressed tablets that loss less 
than 1% of their weight are generally 
considered acceptable. The percentage friability 
for all formulations was below 1% i.e. 
0.12±0.09 %, indicating that the friability is 
within the prescribed limits. The tablets were 
found to contain 104.23±4.15 of the labeled 
amount indicating uniformity of drug content 
(Table V). 
 
Effect of cellulose amount on matrix 
integrity 
The cumulative mean percent of KTR 
released from matrix tablets containing varying 
amounts of ethyl cellulose was showed the 
suitable amount of polymer (10mg) to 
formulate a matrix tablet with good integrity 
and drug release properties. 
Effect of cellulose viscosity grade on 
matrix integrity 
Figure 3 showed the release profiles of 
KTR from the cellulose matrix tablets of 
different viscosity grades (F4-F6). The 
cumulative mean percent of KTR released from 
above formulations was found to vary from 
55.78 to 63.77% after 5h of testing in simulated 
gastric and intestinal fluids and the percent 
drug release was increased gradually after 5h 
and it was found to be 89.34 to 92.23% in 24h.  
 
Effect of eudragit L 100 coating 
To study the effect of the coating level 
on drug release, in vitro dissolution studies in 
different pH (6.7-7.5) media were performed 
on F5 matrix tablets coated with different levels 
(10 to 20% w/w) of Eudragit S100. The 
cumulative mean percent of KTR released from 
above F5 coated formulation was found to vary 
from 7.15±0.52 after 5 h of testing in simulated  
Table V. Drug content uniformity results for proposed formulation 
 
Sl. no. Batch 
code 
Labeled amount of drug 
in each tablet (x) 
Actual drug content (mg) 
in each tablet (y) 
% drug content 
(y/x)100 
1 F1 10 10.37 ± 0.52 103.4 ±1.21 
2 F2 10 10.20±0.21 102.1±1.64 
3 F3 10 10.17±0.09 104.7±1.22 
4 F4 10 10.18±0.09 103.00±1.81 
5 F5 10 11.20±0.26 101.2±2.60 
6 F6 10 9.21±0.24 98.00±1.41 





Figure 3. Comparison of Release profile of KTM from uncoated and Eudragit S100 coated tablets 
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gastric and intestinal fluids and the percent 
drug release was increased gradually after 5h 
and it was found to be complete drug release 
(95.87±0.62%) in 24h.  
 
In-vitro release kinetics 
The values of k, and r2 (correlation 
coefficient of the regression analysis) of zero 
order, first order and Higuchi models of 
designed formulations (Table VI). The n values 
calculated for different formulations were 
found in the range of 0.89-1.02.  
 
Drug-polymer interaction studies 
The FTIR spectrum of pure KTR and 
F1-F6 tablets exhibits a peak at 3487cm-1 is due 
to the N-H and NH2 stretching and peaks at 
1460-1469cm-1, 1482-1495cm-1 is due to C=C 
aromatic and aliphatic stretching, peak at 1371-
1411cm-1 is due to –C-N vibrations, peak                 
at   1045-1060cm-1   is   due   to –OH    bending  
 
confirms presence of alcoholic group, peaks at 
760-800cm-1 confirms the C-H bending 
(aromatic) thus, confirms the structure of drug 
KTR. FTIR of physical mixture showed that 
there is no interaction between drug and the 
polymers employed in formulation. FTIR 
spectra of formulation F5 is given (Figure 4).  
The Differential scanning calorimetry 
(DSC) for trace of drug showed a sharp 
endothermic peak at 169.48°C, its melting 
point. The physical mixture of drug and blank 
microspheres showed the same thermal 
behavior 168.96°C as the individual 
component, indicating that there was no 
interaction between the drug and the polymer 
in the solid state. The absence of endothermic 
peak of the drug at 169.48°C °C in the DSC of 
the drug loaded microspheres suggests that the 
drug existed in an amorphous or disordered 
crystalline phase as a molecular dispersion in 
polymeric matrix. 
  
Table VI. The n values calculated for different formulations according to zero order kinetics 
 
Time / h F 1 F2 F3 F4 F5 F6 
1 1.01 1.02 0.98 1.02 1.00 1.01 
2 1.02 1.01 1.09 0.98 1.02 1.04 
3 1.09 1.06 1.05 1.06 1.84 1.01 
4 1.04 1.00 1.06 1.00 1.66 1.03 
5 1.04 1.01 1.05 1.04 1.63 1.05 
6 1.07 1.00 1.05 1.01 1.62 1.03 
7 1.05 1.00 1.02 1.09 1.59 1.04 
8 1.00 1.05 1.01 1.08 1.56 1.04 
9 1.04 1.09 1.06 1.04 1.53 1.01 
10 1.00 1.01 1.06 1.03 1.50 1.03 
11 1.09 1.05 1.01 1.09 1.48 1.03 
12 1.07 1.00 1.06 1.08 1.46 1.03 
13 1.08 1.06 1.05 1.05 1.46 1.02 
14 1.04 1.01 1.06 1.02 1.45 1.04 
15    1.00 1.45 1.08 
16    1.05 1.42 1.03 
17    1.02 1.40 0.97 
18    1.02 1.37 0.98 
19    1.01 1.30  
20    1.07 1.22  
21    1.08 1.19  
22    1.03 1.12  
23    1.09 1.02  
24    1.02 0.91 . 
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LC Chrmatogram (Figure 5) shows            
that drug was identified free of interference 
from potential impurities and degradation 
products by the absence of any peak in the 
same retention times. There was no 
interference at retention time of Ketorolac due 
to back ground control sample. Retention            
time of KTR in all proposed formulation was 




In view of the potential utility of the 
formulation, stability studies were carried out at 
25°C for six months to assess their stability. 
After storage of three months, the formulation 
was subjected to a drug assay and in vitro 
dissolution studies (Figure 6). 
The angle of repose and % Carr‟s index 
were measured to determine the flow 
properties  of powder mixtures of      formulations 
and the results of angle of repose (<30) and 
compressibility index (<12) indicates fair to 
passable flow properties of the powder mixture 
(Staniforth and Aulton, 2007). In weight 
variation test, the pharmacopoeial limit                 
for the tablets of not more than 7.5% of the 
average weight. The average percentage 
deviation of all tablet formulations was found 
to be within the above mentioned limit and 
hence all formulations passed the uniformity        
of    weight    as    per    official    requirements.  
 
 




Figure 5. Typical UPLC chromatogram of the examined drug (4 μgmL-1) in F5 formulation. Peaks: 
1.78 min (KTR) 
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The hardness and friability are measured for 
tablets strength and integrity. All tablet 
formulations were uniform in hardness, 
friability and drug content uniformity.  
To optimize the polymer content 
different formulations were prepared and 
evaluated for drug release using the ethyl 
cellulose. From the dissolution studies, the 
formulation containing 150mg of cellulose 
showed good drug release pattern in a 
controlled manner for 24 h with good physical 
properties and matrix integrity. Dissolution 
study of F1-F6 shows the effect of different 
viscosity grades of cellulose on release profiles 
of KTR from the cellulose matrix tablets. 
Formulations with cellulose of high viscosity 
 
 
Figure 6. In vitro release study of KTR for the formulation F5 before (blue) and after (red) three 
months storage 
 
Table VII. Estimation of ketorolac tromethamine in new formulation by validated new UPLC 
method 
 




1 0.95 95.33   0.23 
2 1.79 89.44 93.32 9.33 0. 50 




1 1.05 105.19   0.88 
2 2.13 106.57 105.512 12.4 1.93 




1 0.92 91.70   0.35 
2 1.89 94.63 92.50 8.86 0.10 




1 1.09 109.34   0.59 
2 2.18 109.16 109.41 10.95 0.17 




1 1.09 109.34   5.00 
2 2.16 108.12 109.10 13.88 2.63 




1 1.09 108.82   0.50 
2 2.09 104.49 105.56 10.55 0.29 
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formed swollen gel matrix with substantial 
integrity and the drug release was in a 
controlled manner which could be due to the 
better control of water and drug diffusion. In 
comparison with low viscosity grades of ethyl 
cellulose, the tablet lacks strength and was 
eroded quickly after swelling. Investigation 
showed almost 90% drug F1-F3 released in 
stomach and small intestine that doesn‟t 
comply with project aim. Present investigation 
showed 55% drug release in the initial lag 
period and followed by controlled release for 
24h, which is the normal residence time of solid 
dosage form in the colon (Krishnaiah et al., 
1998).18 Formula F4-F5 showed the 
55.78±0.75% drug release in the initial lag 
period (5h) followed by 36.24% (observed 
value – initial released drug; 92.02-55.78%) 
drug release for 24 h in a controlled manner. 
This indicates that a minimal amount of the 
drug (<50%) is released in the physiological 
environment of stomach and small intestine 
and remaining drug release (<50%) was 
observed in colonic region. Thus the 
formulation F4-F5 were considered better 
among other formulations to produce colon 
and gastrointestinal specific drug delivery of 
KTR and it is further improved by Eudragit 
L100 polymeric coating. The drug delivery 
systems targeted to the stomach and small 
intestine should reduce the drug from being 
released in the physiological environment of 
colon (Vyas and Roop, 2006). 
Eudragit L 100, a methacrylate 
copolymer, was selected as the enteric coated 
polymer. It is stable in acidic pH and dissolves 
at pH 7.5, considered as a suitable coating 
material for colonic drug delivery, by retarding 
the drug release at lower gastric and small 
intestine pH values. The lowest coating level to 
obtain a lag time (5h) was found at 20% w/w 
of polymeric coat (F6) to achieve 
gastrointestinal and colon specific drug release.  
After storage of three months, the 
formulation was subjected to a drug assay and 
in vitro dissolution studies. Results show no 
significant degradation due to polymeric 
interaction happened. From the drug release 
kinetics studies, high correlation coefficient 
values for zero order than first order indicating 
that   the  drug  release   from   matrix     tablets  
 
followed zero order profile ensured the release 
of drug from matrix tablets followed diffusion 
mechanism. The „n‟ values calculated for 
different formulations indicating a supercase-II 
transport.  
From the IR spectral analysis all the 
principal peaks observed in pure drug were 
present in the IR spectra of the optimized 
formulation (F4-F6) and no additional peaks 
were observed with physical mixtures, which 
could be due to the presence of polymers. 
These results suggest that there is no 
interaction between the drug and polymers 
used in the present study. This results are also 
confirmed by the identifying the drug in LC 
chromatogram having free of interferences. 
Ketorolac tromethamine in new formulations 
has been estimated by validated new UPLC 
method. Percentage recovery (Table VII) is 
ranged from 92.49-109.4 with very excellent 
RSD of 0.14-5.08%. This indicates that no 
interference occurred due to drug excipients. 
But in accordance to pre- and post-formulation 
investigation, formulation F4 and F5 are 
supposed to be acceptable having property of 
gastrointestinal, colonic drug delivery system. 
After storage of three months and six months, 
the formulation was subjected to a drug assay 
and in vitro dissolution studies and the data 
showed that there was no significant change in 




The physical properties like weight 
variation, thickness, hardness and friability of 
all formulations were comply with 
pharmacopoeia standards, so all the tablets 
were to be acceptable with physical 
characteristics. Dissolution study of F1-F6 
formulations shows the effect of different 
viscosity grades of cellulose on release profiles 
of KTR from the cellulose matrix tablets. 
Formulations F4-F5 were considered to be 
better among other formulations to produce 
KTR delivery through both gastrointestinal and 
colon systems simultaneously and it is further 
improved by Eudragit L100 polymeric coating. 
From the IR spectral and UPLC analysis 
indicate that no interference occurred due to 
drug excipients. 
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